HC Wainwright reaffirmed their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report issued on Monday morning. HC Wainwright currently has a $17.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the company. Piper Jaffray Companies reiterated a sell rating and issued a $14.00 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday. Vetr upgraded Valeant Pharmaceuticals International from a strong sell rating to a sell rating and set a $12.46 price target for the company in a research note on Monday. ValuEngine lowered Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Cantor Fitzgerald reiterated a buy rating and issued a $23.00 price target on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Finally, Mizuho reiterated a sell rating and issued a $7.00 price target (down previously from $8.00) on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $17.62.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 14.07 on Monday. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $27.84. The company’s market capitalization is $4.90 billion. The stock has a 50 day moving average price of $14.22 and a 200-day moving average price of $13.18.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. Valeant Pharmaceuticals International’s revenue was down 7.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.88) EPS. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Earns Hold Rating from HC Wainwright” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-earns-hold-rating-from-hc-wainwright/1576864.html.

In other news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average cost of $14.33 per share, with a total value of $143,300.00. Following the transaction, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Gruss & Co. Inc. purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter worth about $104,000. Harbor Advisors LLC purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter worth about $110,000. WMS Partners LLC purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter worth about $116,000. PNC Financial Services Group Inc. raised its position in Valeant Pharmaceuticals International by 33.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the period. Finally, Baird Financial Group Inc. purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter worth about $127,000. 50.47% of the stock is currently owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.